Browsing Tag
argenx SE
4 posts
First Tracks Biotherapeutics delivers major ANB033 trial win as celiac drug competition intensifies
First Tracks Biotherapeutics stock jumps on positive ANB033 celiac disease trial data. Discover what the results mean for investors and its growth outlook.
Why argenx is buying Forte Biosciences before FB102 enters its bigger proof stage
argenx agrees to buy Forte Biosciences for $2.2 billion. Read how FB102 could reduce Vyvgart concentration risk and reshape ARGX’s autoimmune strategy.
Could FcRn blockers become the next biologics blockbuster class after interleukin inhibitors and JAKs?
A new frontier is emerging in the world of biologic therapies. After years of dominance by interleukin inhibitors…
argenx wins EU approval for subcutaneous VYVGART in CIDP, ending 30-year innovation drought in treatment
argenx gains EU approval for subcutaneous VYVGART in CIDP, reshaping autoimmune neurology care with a novel self-injection biologic.